Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability

Larry K. Golightly 1 , Gerard R. Barber, Michelle A. Barron,  and Robert L. Page II
  • 1 University of Colorado Health Sciences Library/Center for Drug Information, Education and Evaluation, Aurora, CO, USA
  • 2 University of Colorado Hospital, Aurora, CO, USA
  • 3 University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA
  • 4 University of Colorado School of Medicine, Aurora, CO, USA
Larry K. Golightly, Gerard R. Barber, Michelle A. Barron and Robert L. Page II

Abstract

Background: Acute muscle injury and potentially fatal rhabdomyolysis may occur with use of statins and certain interacting medications. This investigation assessed risk for myopathy in patients receiving treatment with a statin in combination with daptomycin, a medication also associated with muscle injury.

Methods: Patients hospitalized from July 1, 2005, through June 30, 2010, who received simvastatin or rosuvastatin concurrently with daptomycin were identified and their medical records were examined. Patients were judged to have treatment-related muscle injury if their records contained evidence of myalgia with or without weakness and secondarily impaired mobility together with elevated creatine kinase (CK) levels. These assessments were compared with similar data from hospitalized patients who received a statin alone.

Results: A total of 52 patients received 66 courses of concurrent treatment with simvastatin or rosuvastatin and daptomycin. Of these, no patient (0%) met evidentiary requirements for diagnosis of myopathy or related complications. No patient (0%) developed muscle pain or discomfort and none developed markedly elevated CK levels. The incidence of asymptomatic elevations of CK in these simvastatin or rosuvastatin plus daptomycin recipients (9%) was statistically indistinguishable from the incidence of CK elevations found in a cohort of 105 inpatients who received simvastatin or rosuvastatin alone (21%; p=0.135).

Conclusions: In patients receiving treatment with simvastatin or rosuvastatin and daptomycin, no symptoms or objective evidence of muscle injury attributable to a drug interaction were identified. These findings are consistent with data indicating that the myopathic effects of statins and daptomycin are incited by disparate and perhaps unique pharmacological mechanisms. Risk of muscle injury therefore appears to be no greater when a statin is administered with daptomycin than when either medication is used alone.

  • 1.

    Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–81.

    • Crossref
  • 2.

    Bulbulia R, Bowman K, Wallendszus K, Parish S, Armitage J, Peto R, et al. Heart protection study collaborative group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,356 high-risk individuals: a randomised controlled trial. Lancet 2011;378:2013–20.

    • Crossref
  • 3.

    Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Heart protection study collaborative group. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. Br Med J 2006;333:1145.

    • Crossref
  • 4.

    Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin [letter]. Ann Intern Med 1991;114:342.

    • Crossref
  • 5.

    Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R, Musso JL. Rhabdomyolysis and simvastatin use [letter]. Nephron 1991;57:365–6.

    • Crossref
    • PubMed
  • 6.

    Bizzaro N, Bagolin E, Lilani L, Cereser C, Finco B. Massive rhabdomyolysis and simvastatin [letter]. Clin Chem 1992;38:1504.

    • Crossref
    • PubMed
  • 7.

    Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient [letter]. Am J Med 2000;108:351–2.

    • Crossref
  • 8.

    Federman DG, Hussain F, Walters JB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 2001;94:1023–6.

    • Crossref
    • PubMed
  • 9.

    Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 2002;35:e111–2.

    • Crossref
  • 10.

    Francis L, Bonilla E, Soforo E, Neupane H, Nakhla H, Fuller C, et al. Fatal toxic myopathy attributed to methylprednisolone and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol 2008;27:129–31.

    • Crossref
    • PubMed
  • 11.

    Schick BA, Laaksonen R, Frohlich JJ, Päiva H, Lehtimäki T, Humphries KH, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007;81:650–3.

    • Crossref
    • PubMed
  • 12.

    Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther 2005;19:403–14.

    • Crossref
  • 13.

    Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781–90.

    • Crossref
  • 14.

    Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658–69.

    • Crossref
  • 15.

    FDA Drug Safety Communication. New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed 16 April 2012.

  • 16.

    Oleson FB Jr., Berman CL, Kirkpatrick JB, Regan KS, Lai J-J, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948–53.

    • Crossref
    • PubMed
  • 17.

    Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673–81.

    • Crossref
    • PubMed
  • 18.

    Patel SJ, Samo TC, Suki WN. Early-onset rhabdomyolysis related to daptomycin use [letter]. Int J Antimicrob Agents 2007;30:472–4.

    • Crossref
  • 19.

    Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, Murphy BS. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006;42:e108–10.

  • 20.

    Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin [letter]. J Antimicrob Chemother 2006;57:578–9.

    • Crossref
  • 21.

    Odero RO, Cleveland KO, Gelfand S. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor [letter]. J Antimicrob Chemother 2009;63:1299–300.

    • Crossref
  • 22.

    Bland CM, Brookstaver PB, Thomas S. Successful re-challenge of daptomycin therapy after initial rhabdomyolysis with co-administration of simvastatin [letter]. Int J Antimicrob Agents 2011;38:549–50.

    • Crossref
  • 23.

    Cubicin® injection [package insert]. Lexington, MA: Cubist Pharmaceuticals Inc, 2012.

  • 24.

    Pasternak RC, Smith SC Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024–8.

  • 25.

    Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674–80.

    • Crossref
    • PubMed
  • 26.

    Rowan C, Brinker AD, Nourjah P, Chang J, Mosholder A, Barrett JS, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009;18:301–9.

    • Crossref
  • 27.

    Vickers S, Duncan CA, Chen I-W, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990;18:138–45.

    • PubMed
  • 28.

    Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157–81.

    • Crossref
  • 29.

    Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003;56: 120–4.

    • Crossref
  • 30.

    Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505–12.

    • Crossref
    • PubMed
  • 31.

    Chen C, Mireles RJ, Campbell SC, Lin J, Mills JB, Xu JJ, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005;33:537–46.

    • Crossref
  • 32.

    Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda I, et al. The Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008;359:789–99.

    • Crossref
  • 33.

    Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The Clinical Pharmacogenomics Implementation Consortium. CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012;92:112–7.

    • Crossref
  • 34.

    Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788–97.

    • Crossref
  • 35.

    Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf 2012;11:439–44.

    • Crossref
  • 36.

    Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract]. J Clin Pharmacol 2000;40:1056.

  • 37.

    McCormick AD, McKillop D, Dutters CJ, Miles GS, Baba T, Touchi A, et al. ZD4522: an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol 2000;40:1055.

  • 38.

    Toth PP, Dayspring TD. Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf 2011;10:969–86.

  • 39.

    Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565–81.

    • Crossref
    • PubMed
  • 40.

    Sacher J, Weigl L, Werner, M, Szegedi C, Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 2005;314:1032–41.

    • Crossref
  • 41.

    Mullen PJ, Lüscher B, Scharnagl H, Krähenbühl, Brecht K. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol 2010;79:1200–9.

    • Crossref
    • PubMed
  • 42.

    Kwak H-B, Thalacker-Mercer A, Anderson EJ, Lin C-T, Kane DA, Lee N-S, et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012;52:198–207.

    • Crossref
  • 43.

    Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009;153:11–6.

    • Crossref
  • 44.

    Fowler VG Jr., Boucher HW, Corey R, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653–65.

    • Crossref
  • 45.

    Bhavani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations of creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010;50: 1568–74.

    • Crossref
  • 46.

    Sbrana F, Di Paolo A, Pasanisi EM, Tagliaferri E, Arvia C, Puntoni M, et al. Administration interval and daptomycin toxicity: a case report of rhabdomyolysis [letter]. J Chemother 2010;22:434–5.

    • Crossref
    • PubMed
  • 47.

    Tally FP, DeBruin MF. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000;46:523–6.

    • Crossref
  • 48.

    DePestel DD, Herschberger E, Lamp KC, Malani PN. Safety and clinical outcomes among older adults receiving daptomycin therapy: insights from a patient registry. Am J Geriatr Pharmacother 2010;8:551–61.

  • 49.

    Benziger DP, Pertel PE, Donovan J, Yankelev S, Schwab RJ, Swan SK, et al. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin Nephrol 2011;75:63–9.

    • PubMed
  • 50.

    Kostrominova TY, Coleman S, Oleson FB, Faulkner JA, Larkin LM. Effect of daptomycin on primary rat muscle cell cultures in vitro. In Vitro Cell Dev Biol Anim 2010;46:613–8.

  • 51.

    Kostrominova TY, Hassett CA, Rader EP, Davis C, Larkin LM, Coleman S, et al. Characterization of skeletal muscle effects associated with daptomycin in rats. Muscle Nerve 2010;42: 385–93.

    • Crossref
    • PubMed
  • 52.

    Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 1992;36:318–25.

  • 53.

    Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004;150:137–47.

    • Crossref
  • 54.

    Parra-Ruiz J, Dueñas-Gutiérrez C, Tomás-Jiménez C, Linares-Palomino JP, Garrido-Gomez J, Hernández-Quero J. Safety analysis of high-dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. Eur J Clin Microbiol Infect Dis 2012;31:1771–4.

    • Crossref
Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Drug Metabolism and Personalized Therapy (DMPT ) publishes the results of research and review articles in the fields of clinical and biological pharmacology, drug metabolizing enzymes, pharmacogenetics/pharmacogenomics, pharmacokinetics and drug-drug interactions. DMPT is the official journal of the European Society of Pharmacogenomics and Personalised Therapy.

Search